US EditionPublished • loading... • Updated
Pioneering Gene Editing CRISPR Therapeutics Unveils Groundbreaking Data for CTX460 in Combatting Alpha-1 Antitrypsin ...
Summary by csimarket.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Pioneering Gene Editing CRISPR Therapeutics Unveils Groundbreaking Data for CTX460 in Combatting Alpha-1 Antitrypsin ...
In an era where gene editing stands at the forefront of medical innovation, CRISPR Therapeutics AG has garnered attention for its recent revelations concerning CTX460, a revolutionary therapeutic candidate designed to combat Alpha-1 Antitrypsin Deficiency (AATD). At the recent European Society of Gene and Cell Therapy (ESGCT) congress, the company unveiled preclinical data demonstrating the efficacy of its novel SyNTase editing platform in achie…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
